Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock price drop, with a decline exceeding 70% following a notification from the Hong Kong Stock Exchange regarding insufficient operational levels and asset value to support continued listing [1][2]. Group 1: Company Announcement and Stock Performance - On November 14, 2025, the company received a letter from the Stock Exchange indicating that it failed to maintain sufficient operational levels and asset value, leading to a decision to suspend trading of its shares on November 26, 2025 [2][3]. - The company had previously announced a failed placement agreement to issue up to 145 million shares at HKD 0.415 per share, as the conditions precedent were not met by September 11, 2025 [1][3]. Group 2: Financial Performance - For the fiscal year ending March 31, 2025, the company reported a revenue of HKD 2.091 million, a year-on-year decrease of 68.28%, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [5]. - The basic earnings per share for the reporting period were -HKD 0.2001, with net cash flow from operating activities at -HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [5].

Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock crash, with a drop exceeding 70% due to regulatory actions from the Hong Kong Stock Exchange regarding its operational viability and asset value [2][5][9]. Company Announcement - On November 14, 2025, Starcoin Group received a notification from the Hong Kong Stock Exchange stating that it failed to maintain sufficient operational levels and asset value, leading to a suspension of its shares on November 26, 2025, unless a review is requested [4][6]. - The company announced that a planned share placement of up to 145 million shares at HKD 0.415 per share has become void due to unmet conditions by September 11, 2025, terminating all responsibilities between the placement agent and the company [2][7]. Financial Performance - For the fiscal year ending March 31, 2025, Starcoin Group reported a revenue of HKD 2.091 million, a decline of 68.28% year-on-year, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [10]. - The basic earnings per share for the reporting period was -HKD 0.2001, with a net cash outflow from operating activities of HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [10]. Company Background - Starcoin Group operates in the pharmaceutical and biotechnology sector, with five divisions including genetic testing services, bioproduct distribution, beauty equipment trade, securities investment, and research on oral insulin products [9]. - The company had previously seen a significant stock price increase of nearly 100% during June to July 2025 before entering a downward trend [9].

Group 1 - The company has signed two memorandums of understanding (MOUs) to explore new business opportunities in blockchain technology and digital innovation [1][2] - The first MOU is with Supernova, focusing on developing and managing blockchain-based systems and related token issuance under applicable U.S. laws, as well as representing Supernova in projects related to AQP functional water technology [1][2] - The second MOU is with Scaling Lab, aimed at collaborating on scientific research related to the genetic epidemiology and physiology of cardiovascular diseases and their risk factors, particularly diabetes [1][2] Group 2 - The company is actively seeking to diversify its revenue sources and enhance performance through strategic plans, including expanding into the blockchain technology sector [2] - The collaboration with Supernova is expected to facilitate entry into the digital innovation industry and develop a new business segment [2] - The partnership with Scaling Lab is intended to strengthen the company's diabetes solution development and support the exploration of new business opportunities [2]

Group 1 - The company has signed two memorandums of understanding (MOUs) to explore collaborations in blockchain technology and health-related research [1][2] - The first MOU is with Supernova, focusing on developing and managing blockchain-based systems and token issuance under applicable U.S. laws, as well as representing Supernova in projects related to AQP functional water technology [1][2] - The second MOU is with Scaling Lab, aimed at scientific research collaboration on genetic epidemiology and physiology of cardiovascular diseases, particularly concerning diabetes and its treatment methods [1][2] Group 2 - The company is an investment holding firm actively seeking new business opportunities to diversify revenue sources and enhance performance [2] - The collaboration with Supernova is intended to advance the company's entry into the digital innovation sector, indicating a strategic move towards blockchain technology [2] - The partnership with Scaling Lab is expected to strengthen the company's research capabilities in diabetes solutions and support the exploration of new business opportunities [2]

Core Viewpoint - The stock of Vanguard Medical Biotechnology (00399) experienced a significant decline of 7.69%, trading at HKD 0.42 per share with a transaction volume of HKD 5.9847 million as of 10:26 AM on August 21 [1] Company Overview - Vanguard Medical Biotechnology focuses on the research and development of oral insulin products, as well as the trade of beauty instruments and products [1] - The company is committed to acquiring commercially viable pharmaceutical products and was formerly known as United Gene Technology Group [1] - It is currently listed on the main board of the Hong Kong Stock Exchange under stock code 399 [1] Financial Performance - As of the 2024 annual report, Vanguard Medical Biotechnology reported total revenue of HKD 1.9296 million and a net loss of HKD 319 million [2]

Group 1 - The stock price of Jingyou Pharmaceutical (00858) increased by 20.34% on August 15, reaching HKD 0.142 per share with a trading volume of HKD 6.8024 million [1] - Jingyou Pharmaceutical Holdings Limited primarily promotes and sells pharmaceutical products in the Chinese market, develops gene-related technologies, and works on oral insulin products through joint ventures [1] - The company is listed on the main board of the Hong Kong Stock Exchange and is registered in Bermuda [1] Group 2 - As of the 2024 annual report, Jingyou Pharmaceutical reported total revenue of HKD 51.1515 million and a net profit of HKD 205 million [2]

Core Viewpoint - The stock of Pioneer Pharma Biotechnology (00399) experienced a decline of 6.35% on August 1, trading at HKD 0.59 per share with a transaction volume of HKD 1.093 million [1]. Group 1: Company Overview - Pioneer Pharma Biotechnology focuses on the research and development of pharmaceutical products and the trade of beauty instruments and products, particularly oral insulin products [1]. - The company is actively seeking pharmaceutical products with commercial development potential to expand its research and development scope [1]. - Pioneer Pharma is listed on the main board of the Hong Kong Stock Exchange under stock code 399 [1]. Group 2: Financial Performance - As of the 2024 annual report, Pioneer Pharma Biotechnology reported total revenue of HKD 1.9296 million and a net loss of HKD 319 million [2].

Group 1 - The core viewpoint of the article highlights the recent stock performance of Jingyou Pharmaceutical, which saw a 5.47% increase, reaching a price of 0.135 HKD per share with a trading volume of 2.3585 million HKD [1] - Jingyou Pharmaceutical Holdings Limited primarily focuses on promoting and selling pharmaceutical products in the Chinese market, researching gene-related technologies, and developing oral insulin products through joint ventures [1] - As of the 2024 annual report, Jingyou Pharmaceutical reported total revenue of 51.1515 million HKD and a net profit of 205 million HKD [2]

Group 1 - The core business of the company includes the research and development of pharmaceutical products and the trade of beauty instruments and products, with a particular focus on oral insulin products [1] - As of July 30, the company's stock price increased by 6.15%, reaching HKD 0.69 per share, with a trading volume of HKD 9.672 million [1] - For the fiscal year ending 2024, the company reported total revenue of HKD 1.9296 million and a net loss of HKD 319 million [2]

Company Overview - The company, Leading Pharmaceutical Biotechnology (00399.HK), closed at HKD 0.39 per share, marking a 39.29% increase with a trading volume of 113 million shares and a turnover of HKD 38.66 million, reflecting a volatility of 39.29% [1] - Over the past month, Leading Pharmaceutical Biotechnology has seen a cumulative increase of 36.59%, and a year-to-date increase of 34.62%, outperforming the Hang Seng Index by 20.65% [1] Financial Performance - As of March 31, 2025, Leading Pharmaceutical Biotechnology reported total revenue of HKD 1.9296 million, a decrease of 68.28% year-on-year [1] - The company recorded a net profit attributable to shareholders of -HKD 319 million, a significant decline of 434.55% year-on-year [1] - The gross profit margin stood at 8.99%, with a debt-to-asset ratio of 97.66% [1] Industry Valuation - Currently, there are no institutional investment ratings for Leading Pharmaceutical Biotechnology [2] - The average price-to-earnings (P/E) ratio for the consumer retail sector (TTM) is -0.32x, with a median of 2.04x; Leading Pharmaceutical Biotechnology has a P/E ratio of -1.49x, ranking 13th in the industry [2] - Comparatively, other companies in the sector have P/E ratios such as Minghui International (4.36x), Youpin 360 (7.76x), Hengan International (10.97x), Jiangsu Hongxin (12.35x), and China Jindian Group (17.15x) [2] Business Segments - Leading Pharmaceutical Biotechnology's operations are primarily divided into two segments: research and development of pharmaceutical products and trade of beauty instruments and products [2] - The company is currently focused on developing oral insulin products and aims to acquire more commercially viable pharmaceutical products to expand its R&D scope [2] - Previously known as United Gene Technology Group, the company primarily provided genetic testing services, health management services, and distribution of biotechnology products [2]